PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25676404-2	2015	The aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9 human lung adenocarcinoma cells to common chemtherapeutic drugs including ciaplatin, gemcitabine, paclitaxel, pemetrexed and vinorelbine, and to elucidate possible mechanisms.	Pemetrexed	210-220	proprotein convertase subtilisin/kexin type 9	Homo sapiens	96-99	
27006151-4	2016	RESULTS: Simultaneous treatment with gefitinib and pemetrexed enhanced cell growth inhibition and cell death and prevented the appearance of gefitinib resistance mediated by T790M mutation or epithelial-to-mesenchymal transition (EMT) in PC9 and HCC827 cells, respectively.	Pemetrexed	51-61	proprotein convertase subtilisin/kexin type 9	Homo sapiens	238-241	
27006151-5	2016	In PC9 cells and in PC9 xenografts the combination of gefitinib and pemetrexed, with different schedules, prevented gefitinib resistance only when pemetrexed was the first treatment, given alone or together with gefitinib.	Pemetrexed	68-78	proprotein convertase subtilisin/kexin type 9	Homo sapiens	3-6	
27006151-5	2016	In PC9 cells and in PC9 xenografts the combination of gefitinib and pemetrexed, with different schedules, prevented gefitinib resistance only when pemetrexed was the first treatment, given alone or together with gefitinib.	Pemetrexed	68-78	proprotein convertase subtilisin/kexin type 9	Homo sapiens	20-23	
24840891-7	2014	In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line.	Pemetrexed	85-95	proprotein convertase subtilisin/kexin type 9	Homo sapiens	170-173	
24840891-7	2014	In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line.	Pemetrexed	85-95	proprotein convertase subtilisin/kexin type 9	Homo sapiens	270-273	
30838090-2	2019	To elucidate the mechanisms of pemetrexed resistance in lung cancer, we established pemetrexed-resistant sublines in PC9 (mutant EGFR) and H1993 (wild-type EGFR) lung adenocarcinoma cell lines (PC9-MTA, H1993-MTA).	Pemetrexed	84-94	proprotein convertase subtilisin/kexin type 9	Homo sapiens	117-120	
30838090-2	2019	To elucidate the mechanisms of pemetrexed resistance in lung cancer, we established pemetrexed-resistant sublines in PC9 (mutant EGFR) and H1993 (wild-type EGFR) lung adenocarcinoma cell lines (PC9-MTA, H1993-MTA).	Pemetrexed	84-94	proprotein convertase subtilisin/kexin type 9	Homo sapiens	194-197	
30838090-6	2019	SiRNA-mediated FGF2 knockdown partially restored pemetrexed sensitivity in both lines, whereas anti-FGFR1 inhibitor PD173074 restored pemetrexed sensitivity in PC9-MTA.	Pemetrexed	134-144	proprotein convertase subtilisin/kexin type 9	Homo sapiens	160-163	
29393480-7	2018	In addition, PC-9/GR cells were less sensitive to chemotherapeutic drugs tested, including cisplatin, gemcitabine, pemetrexed, paclitaxel and docetaxel, compared to PC-9 and PC-9/ZD cells.	Pemetrexed	115-125	proprotein convertase subtilisin/kexin type 9	Homo sapiens	13-17